Repligen (RGEN) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Repligen (RGEN) over the past year, gaining 363.7% versus a gain of 8.6%. Over five years, TWST leads with a +34.8% price change compared with -38.6% for RGEN. Repligen is the larger company by market cap ($10.99 billion vs $10.78 billion), about 1.0 times the size, while Twist Bioscience is growing revenue faster (+20.3% vs +16.4%).
Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGEN | TWST |
|---|---|---|
| Share price | $173.05 | $162.52 |
| Market cap | $10.99B | $10.78B |
| 1-day change | +5.62% | +6.89% |
| YTD return | -0.01% | +379.35% |
| 1-year return | +8.64% | +363.71% |
| 5-year return | -38.62% | +34.80% |
| P/E ratio (TTM) | 237.05 | — |
| Forward P/E | 65.36 | — |
| EPS (TTM) | $0.73 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $738.26M | $376.57M |
| Revenue growth (YoY) | +16.36% | +20.32% |
| Net income (latest FY) | $48.89M | $-77.67M |
| Gross margin | 52.32% | 50.72% |
| Operating margin | 7.47% | -36.18% |
| Net margin | 6.62% | -20.63% |
| 52-week high | $198.87 | $219.71 |
| 52-week low | $100.99 | $23.30 |
| Distance from 52-week high | -12.98% | -26.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +12.66% | -7.50% |
| Average volume | 1.18M | 2.04M |
| Shares outstanding | 63.49M | 66.30M |
| Employees | 2,000 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed RGEN by 355.1 percentage points over the past year.
- Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
RGEN vs TWST FAQ
Which is bigger, Repligen or Twist Bioscience?
Repligen (RGEN) is larger, with a market capitalization of $10.99B compared with $10.78B for Twist Bioscience (TWST).
Which stock has performed better over the past year, RGEN or TWST?
TWST returned +363.71% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Repligen and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.